Skip to main content
MyDeficiencies

Diazoxide

Endocrine, hypoglycemia agent, benzothiadiazine KATP-channel opener (non-diuretic)

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Diazoxide has essentially no classical drug-nutrient depletion machinery, and its own pharmacokinetic profile explains why. Its FDA label documents no cytochrome P450 induction or inhibition and no significant hepatic metabolism; it is cleared renally, largely unchanged, with a long half-life (24 to 36 hours in adults, longer with renal impairment); and it produces no described chelation, gastric-pH, bile-acid-sequestration, or transit-time mechanism for classical vitamin or mineral loss. Drug-specific searches for carnitine, thiamine, and vitamins in general returned no study combining diazoxide with any of them. What the label does document, directly and as one of the drug's most common adverse effects, is the opposite of depletion: diazoxide suppresses renal excretion of sodium and water (an intrinsic antidiuretic property, not a secondary hormonal cascade), producing dose-related fluid and sodium retention that can precipitate congestive heart failure in a patient with compromised cardiac reserve. This is graded red in this dossier, on two independent Tier A sources with diazoxide specifically in the cohort, but it is graded as an excess/retention risk, never as a rationale for sodium supplementation.

Endocrine, hypoglycemia agent, benzothiadiazine KATP-channel opener (non-diuretic) · ATC V03AH01 · also sold as Proglycem (oral suspension and Teva) · reviewed 2026-09-28. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Diazoxide in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Sodium and fluid retention, dose-related antidiuretic effect

Red — Severe

See study details

Diazoxide directly suppresses renal excretion of sodium and water. Its own FDA label and an independent human cohort study, both with diazoxide specifically as the studied drug, confirm dose-related fluid and sodium retention that can be clinically significant, more frequent at higher or longer-term dosing and less frequent at reduced starting doses; this is an excess-risk finding, never a rationale for sodium supplementation.

Full detail, limits and 2 references

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. red

Limits on what this shows

  • Key negative/null findings: The Chandran 2022 low-dose cohort found a comparatively low absolute frequency (3.7 percent), suggesting the retention effect is dose-dependent and less common at reduced starting doses than the general label language implies at higher or longer-term dosing; no study located directly measured diazoxide at standard or maximum labeled doses against a matched no-treatment comparator.
  • At-risk subgroups: Infants and patients with compromised cardiac reserve (label-stated risk of precipitating congestive heart failure); renal impairment, where the prolonged half-life compounds retention and dose reduction is advised; concurrent thiazide use, which offsets fluid retention pharmacologically but potentiates diazoxide's hyperglycemic and hyperuricemic effects.

Regulatory status

FDA label (Warnings, Adverse Reactions) states that diazoxide "decreases the excretion of sodium and water, resulting in fluid retention which may be clinically significant," listed among the most common adverse effects in both infants and adults, and warns it "may precipitate congestive heart failure" in patients with compromised cardiac reserve.

Population evidence

Chandran S, R PR, Mei Chien C, Saffari SE, Rajadurai VS, Yap F. Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia. Arch Dis Child Fetal Neonatal Ed, 2022. PMID 34544689. Human cohort, diazoxide specifically studied at a reduced/low-dose regimen in small-for-gestational-age infants; fluid retention observed in 1 infant (3.7 percent of the cohort) and generalized hypertrichosis in 2 (7.4 percent). Keyes ML, Healy H, Sparger KA, Orth LE, Geha M, Roumiantsev S, Matute JD. Necrotizing Enterocolitis in Neonates With Hyperinsulinemic Hypoglycemia Treated With Diazoxide. Pediatrics, 2021. PMID 33483452. Case series of diazoxide-treated neonates, lists fluid retention among the drug's known adverse effects without providing an independent frequency estimate.

Mechanism

Named. Direct renal tubular antidiuretic effect (reduced sodium and water excretion), described in the label as an intrinsic pharmacologic property of the drug itself rather than a secondary aldosterone or ADH-mediated cascade.

Counter-evidence held on record

No study located found diazoxide free of a sodium/fluid-retention signal; the two independent Tier A sources agree on direction even though their reported frequency differs by dose and population studied. This is a retention hazard from the drug's own antidiuretic pharmacology, not a nutritional sodium deficiency, and must never be read as a reason to add dietary or supplemental sodium. The correct response is monitoring for edema, weight gain, and heart-failure signs, and prescriber-directed diuretic co-therapy or dose reduction, not supplementation in either direction.

KATP channel activation enhancing DMT1-mediated iron uptake

Yellow — Low

See study details

One in vitro neuronal cell-line study found that pharmacological KATP channel activation with diazoxide increased divalent metal transporter 1 (DMT1)-mediated iron uptake. This is a narrow mechanistic signal, not evidence of clinical iron loading or iron deficiency in patients taking diazoxide.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No confirming or contradicting second study located. A combined PubMed search for diazoxide with copper, iron, ferritin, or ceruloplasmin returned results only for this single iron/DMT1 study; a standalone "diazoxide copper" search returned zero results (see Copper entry).
  • At-risk subgroups: Theoretical only; no clinical population identified, and the cell line used (SK-N-SH, neuroblastoma) is not directly representative of the intestinal or hepatic tissue most relevant to whole-body iron status.

Regulatory status

Not addressed in the FDA label; no iron-related adverse effect or interaction is listed.

Population evidence

Du X, Xu H, Shi L, et al. Activation of ATP-sensitive potassium channels enhances DMT1-mediated iron uptake in SK-N-SH cells in vitro. Sci Rep, 2016, PMID 27646472. SK-N-SH human neuroblastoma cells in vitro, diazoxide-mediated KATP channel activation enhanced DMT1-mediated iron uptake. Single study, cell-line model; no human or in vivo animal confirmation located.

Mechanism

Named. KATP channel activation modulating DMT1 transporter activity, increasing cellular iron uptake rather than causing loss.

Counter-evidence held on record

No replication was located; a single in vitro study in an unrepresentative cell line is a real but narrow signal. Not a basis for changing iron intake or supplementation in either direction. This finding runs in the increased-uptake, not deficiency, direction and is flagged only as a research signal potentially relevant to a patient who independently has a hereditary iron-overload condition; it is not, by itself, reason for concern in routine use.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial KATP channel opening, preserved mitochondrial structure/function under ischemic stress

Yellow — Low

See study details

Diazoxide is a well-characterized pharmacological opener of the mitochondrial ATP-sensitive potassium (mitoKATP) channel. A consistent animal and in vitro literature using this drug specifically shows it preserving mitochondrial structure and function under ischemic, hypoxic, or toxic stress, the opposite of a depletion signal, though none of this has been tested in humans at the drug's approved oral hypoglycemia dosing.

Full detail, limits and 5 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: Droese S, Hanley PJ, Brandt U. Ambivalent effects of diazoxide on mitochondrial ROS production at respiratory chain complexes I and III. Biochim Biophys Acta, 2009, PMID 19364480, in vitro mechanistic study, found diazoxide can also interfere with the electron transport chain independent of, and at times opposite to, its mitoKATP-mediated protective action at higher concentrations, so the direction is not uniformly protective across all conditions studied.
  • At-risk subgroups: None identified in humans; all data preclinical, generally using research concentrations and acute ischemic-stress models, not the sustained, low-concentration oral exposure used for hypoglycemia treatment.

Regulatory status

Not addressed in the FDA label, which describes only the pancreatic beta-cell and vascular smooth-muscle KATP actions relevant to diazoxide's glucose-raising effect.

Population evidence

No human clinical trial located; all evidence is Tier B, animal or in vitro, with diazoxide specifically used as the pharmacological agent. Pan Y, Wang Y, Shi W, Liu Y, Cao S, Yu T. Mitochondrial proteomics alterations in rat hearts following ischemia/reperfusion and diazoxide post-conditioning. Mol Med Rep, 2021, PMID 33355377, rat hearts, diazoxide post-conditioning preserved the mitochondrial proteome after ischemia/reperfusion. Iwai T, Tanonaka K, Koshimizu M, Takeo S. Preservation of mitochondrial function by diazoxide during sustained ischaemia in the rat heart. Br J Pharmacol, 2000, PMID 10725271, rat hearts, diazoxide preserved mitochondrial function during sustained ischemia. Wang Y, Qi M, McGarrigle JJ, et al. Diazoxide Preconditioning of Nonhuman Primate Pancreas Improves Islet Isolation Outcomes by Mitochondrial Protection. Pancreas, 2020, PMID 32433410, nonhuman primate pancreas, diazoxide preconditioning improved islet-isolation outcomes via mitochondrial protection. Akopova O, Kolchinskaya L, Nosar V, Mankovska I, Sagach V. Diazoxide affects mitochondrial bioenergetics by the opening of mKATP channel on submicromolar scale. BMC Mol Cell Biol, 2020, PMID 32306897, isolated mitochondria, submicromolar diazoxide opened mitoKATP and altered bioenergetics.

Mechanism

Named. mitoKATP channel opening reduces mitochondrial calcium overload and preserves membrane potential during ischemic stress, the same channel family, though a different tissue distribution, as the pancreatic beta-cell KATP channel diazoxide is prescribed to open.

Counter-evidence held on record

The Droese et al. 2009 ambivalent/off-target finding is the main counter-evidence, arguing against a simple "diazoxide protects mitochondria" narrative even within the preclinical literature. This is preclinical pharmacology, often using diazoxide as an experimental tool compound at research concentrations in ischemia models, not evidence about the standard oral hypoglycemia dosing regimen. It must not be read by a consumer as "diazoxide protects your mitochondria," and it shares part of its evidentiary basis with the Oxidative stress and ATP production entries below; see Overlap map.

Oxidative Stress

Each finding below is counted once, in this area only.

Reduced oxidative-stress markers in preclinical cardiac and neural models

Yellow — Low

See study details

Multiple drug-specific animal and in vitro studies show diazoxide lowering H2O2 and superoxide markers and raising mitochondrial superoxide dismutase activity under hypertrophy, toxic, and hypoxic stress. No human data exist, and this is not evidence of an antioxidant effect at oral hypoglycemia dosing.

Full detail, limits and 5 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: Droese et al. 2009 (PMID 19364480, shared with the Mitochondrial burden entry) found diazoxide can also increase ROS at complex III under some conditions, an ambivalent rather than uniformly antioxidant effect.
  • At-risk subgroups: None identified in humans.

Regulatory status

Not addressed in the FDA label.

Population evidence

Tier B only. Lucas AMB, de Lacerda Alexandre JV, Araujo MTS, et al. Diazoxide Modulates Cardiac Hypertrophy by Targeting H2O2 Generation and Mitochondrial Superoxide Dismutase Activity. Curr Mol Pharmacol, 2020, PMID 31340743, Swiss mice, diazoxide reduced H2O2 generation and improved mitochondrial SOD activity in a cardiac-hypertrophy model. Lemos Caldas FR, et al. Mitochondrial ATP-Sensitive Potassium Channel Opening Inhibits Isoproterenol-Induced Cardiac Hypertrophy. J Cardiovasc Pharmacol, 2015, PMID 25850726, Swiss mice, diazoxide-induced mitoKATP opening reduced oxidative markers and restored SOD activity. Guven C, et al. Diazoxide Attenuates Doxorubicin-Induced Cardiotoxicity in Cultured Rat Myocytes. Biotech Histochem, 2024, PMID 38439686, rat myocytes in vitro, diazoxide attenuated doxorubicin-induced oxidative cardiotoxicity. Rajapakse N, et al. Diazoxide Pretreatment Induces Delayed Preconditioning in Astrocytes. J Neurosci Res, 2003, PMID 12836163, astrocytes in vitro, diazoxide preconditioning was protective against oxidative stress.

Mechanism

Named. mitoKATP-linked reduction in mitochondrial ROS generation with preserved antioxidant enzyme (SOD) activity, mechanistically continuous with the Mitochondrial burden entry above.

Counter-evidence held on record

As above, the Droese et al. finding is a direct counter to a uniformly protective narrative. Preclinical and mechanistic only; not a basis for antioxidant-supplementation claims, and not a basis for reassuring a patient that diazoxide protects against oxidative stress in ordinary use. Shares its core mitoKATP evidence base with the Mitochondrial burden and ATP production entries; see Overlap map.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Not graded — disclosed evidence gap

See study details

No diazoxide-specific evidence at any tier, and no circulating consumer claim, was located for diazoxide and copper status.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Dual condition met. A standalone PubMed search for "diazoxide copper" returned zero results. A broader combined search for diazoxide with copper, iron, ferritin, or ceruloplasmin together returned results only for the unrelated iron/DMT1 study cited in the Iron entry above, with nothing touching copper specifically. No circulating consumer nutrient-depletion claim naming diazoxide and copper was found on the consumer source checked (Drugs.com side-effects page).

Channels tried

PubMed search-listing pages (two phrasings: "diazoxide copper" alone, and "diazoxide AND (copper OR iron OR ferritin OR ceruloplasmin)"), both returning clean zero/off-target results rather than blocked pages; consumer-claim audit (Drugs.com, no claim found). Europe PMC REST API, Semantic Scholar Graph API, Crossref API, and OpenAlex API were attempted as cross-check channels for this category, and for every other category in this review, and returned HTTP 403 (network egress policy denial or upstream failure, per the session's proxy status output) or HTTP 429 (target-side rate limiting) on every attempt across multiple wait-and-retry cycles; they could not be used to independently corroborate this gap.

Genuine gap vs. tooling-limited

Mixed, disclosed plainly. The PubMed signal itself was clean, a real zero-result page and a real off-target result set, not an error page, which supports a genuine absence of drug-specific copper literature. However, the four cross-check APIs this project's protocol calls for were entirely unavailable throughout this session, so this gap should be treated as provisional pending a revision that can reach those channels, rather than a fully closed question.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No diazoxide-specific or genuinely on-topic class-level evidence, and no circulating consumer claim, about diazoxide and the gut microbiome were located.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

  • Why no grade: Dual condition met. A PubMed search combining diazoxide with microbiome, microbiota, or gut flora returned only 3 results, none of which examine diazoxide and gut microbiota together: a setmelanotide trial that mentions diazoxide only as an unrelated comparator drug, a colorectal-cancer microbiota study with no diazoxide connection, and a post-bariatric-hypoglycemia review with no diazoxide connection. No circulating consumer claim was found on the consumer source checked.

Channels tried

PubMed search-listing page (one combined-term query, a clean, fully reviewable result set, off-target rather than blocked); consumer-claim audit (Drugs.com, no claim found); PK-based mechanistic reasoning (diazoxide is orally absorbed but is not described in its label as chelating, altering gastric pH, or otherwise disrupting gut flora directly, which independently limits mechanistic plausibility). Europe PMC, Semantic Scholar, Crossref, and OpenAlex were unavailable for this category for the same session-wide reason disclosed under Copper above.

Genuine gap vs. tooling-limited

Predominantly genuine. The single PubMed query returned a small, clean, fully reviewable result set that was topically off-target rather than empty or blocked, a stronger signal than a failed search; combined with the absence of a chelation/pH/microbiome-disruption mechanism in the label, this supports a real absence of drug-specific evidence. The unreachable cross-check APIs remain a disclosed, residual limitation for a future revision to re-check.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

Decreased hemoglobin / hematocrit, a labeled hematologic effect

Orange — Moderate

See study details

The FDA label lists decreased hemoglobin and hematocrit as a diazoxide-specific hematologic adverse effect. No frequency is given and no dedicated study quantifying this signal was located, so it is graded as real but bounded rather than severe.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit. orange

Limits on what this shows

  • Key negative/null findings: None located specific to this signal. The absence of a dedicated quantifying study limits confidence in magnitude, but the label's own listing is direct, drug-specific Tier A evidence that the effect exists.
  • At-risk subgroups: Not specified in the label; no subgroup guidance located.

Regulatory status

FDA label, Adverse Reactions/Hematologic section, lists "decreased hemoglobin/hematocrit" alongside thrombocytopenia (with or without purpura), transient neutropenia, eosinophilia, and decreased IgG; frequency not reported for any of these.

Population evidence

No dedicated interventional or observational study quantifying diazoxide-associated hemoglobin or hematocrit decline was located. A direct PubMed search for "diazoxide hemoglobin anemia" returned zero results.

Mechanism

Not established in the label or in any source located during this review. Distinct from diazoxide's intended pharmacologic action (pancreatic beta-cell insulin suppression), which has no described link to erythropoiesis, so this is not the drug's own intended mechanism wearing a different name.

Counter-evidence held on record

No contradicting Tier A source was located; the gap here is in quantification, not in the direction of the finding. This is a labeled hematologic monitoring point, not evidence of iron, B12, or folate deficiency. An anemia workup in a patient on diazoxide should not default to a nutrient-deficiency explanation without independent iron/B12/folate testing, since no source located here ties this specific hematologic effect to nutrient status.

Preserved mitochondrial ATP during ischemic or isolation stress in animal models

Yellow — Low

See study details

Animal studies using diazoxide specifically show preserved myocardial and pancreatic-islet ATP content during ischemic or isolation stress via mitoKATP channel opening. No human data exist for the oral hypoglycemia-treatment population this drug is actually prescribed to.

Full detail, limits and 2 references

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow

Limits on what this shows

  • Key negative/null findings: No dedicated null-result study located. The Droese et al. 2009 ambivalent-ROS finding (shared with the Mitochondrial burden and Oxidative stress entries) is a relevant caveat against assuming uniform benefit across all conditions and concentrations.
  • At-risk subgroups: None identified in humans.

Regulatory status

Not addressed in the FDA label.

Population evidence

Iwai T, Tanonaka K, Koshimizu M, Takeo S. Br J Pharmacol, 2000, PMID 10725271 (shared with the Mitochondrial burden entry), rat hearts, diazoxide preserved mitochondrial function and ATP content during sustained ischemia. Wang Y, Qi M, McGarrigle JJ, et al. Pancreas, 2020, PMID 32433410 (shared with the Mitochondrial burden entry), nonhuman primate pancreas, diazoxide preconditioning improved islet-isolation outcomes via mitochondrial protection, consistent with a preserved cellular energy state.

Mechanism

Named. mitoKATP channel opening limits mitochondrial calcium overload and preserves oxidative-phosphorylation capacity during ischemic or isolation stress.

Counter-evidence held on record

No contradicting Tier A or B source was located specific to ATP content, though the broader ambivalent-ROS caveat above applies to the same underlying mechanism. Preclinical ischemia/isolation-model pharmacology, not evidence relevant to routine oral dosing for hypoglycemia; must not be marketed or read as an "energy" benefit of this medication. Shares its entire evidentiary basis with the Mitochondrial burden entry; see Overlap map.

All references used above
  1. DailyMed. PROGLYCEM (diazoxide) oral suspension, Teva Pharmaceuticals USA, Inc., SPL. — FDA label (Tier A). Source for Mechanism of Action, Pharmacokinetics, Adverse Reactions (sodium/fluid retention, hematologic effects, hirsutism), Drug Interactions (thiazides, diphenylhydantoin, coumarin anticoagulants), Warnings (antidiuretic property, ketoacidosis, abnormal facial features, pulmonary hypertension), Renal Impairment dosing, and Pregnancy/Nursing.
  2. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index, V03AH01 diazoxide. — Confirms ATC classification V03AH01, within "Drugs for treatment of hypoglycaemia" (V03AH), under "All other therapeutic products" (V03A/V03).
  3. Chandran S, R PR, Mei Chien C, Saffari SE, Rajadurai VS, Yap F. Safety and efficacy of low-dose diazoxide in small-for-gestational-age infants with hyperinsulinaemic hypoglycaemia. — Human cohort, diazoxide specifically studied (Tier A for this drug). Primary population-evidence source for the Sodium/fluid retention entry: fluid retention in 1 infant (3.7 percent), hypertrichosis in 2 (7.4 percent).
  4. Keyes ML, Healy H, Sparger KA, Orth LE, Geha M, Roumiantsev S, Matute JD. Necrotizing Enterocolitis in Neonates With Hyperinsulinemic Hypoglycemia Treated With Diazoxide. — Case series, diazoxide-treated neonates. Supporting source for the Sodium/fluid retention entry (fluid retention listed among known diazoxide adverse effects).
  5. Pan Y, Wang Y, Shi W, Liu Y, Cao S, Yu T. Mitochondrial proteomics alterations in rat hearts following ischemia/reperfusion and diazoxide post-conditioning. — Animal study (rat hearts, Tier B). Source for the Mitochondrial burden entry.
  6. Akopova O, Kolchinskaya L, Nosar V, Mankovska I, Sagach V. Diazoxide affects mitochondrial bioenergetics by the opening of mKATP channel on submicromolar scale. — In vitro, isolated mitochondria (Tier B). Source for the Mitochondrial burden entry.
  7. Iwai T, Tanonaka K, Koshimizu M, Takeo S. Preservation of mitochondrial function by diazoxide during sustained ischaemia in the rat heart. — Animal study (rat hearts, Tier B). Shared primary source for the Mitochondrial burden and ATP production entries; see Overlap map.
  8. Wang Y, Qi M, McGarrigle JJ, Xing Y, Mendoza-Elias JE, Bochenek M, Marchese E, He Y, Oberholzer J. Diazoxide Preconditioning of Nonhuman Primate Pancreas Improves Islet Isolation Outcomes by Mitochondrial Protection. — Animal study (nonhuman primate, Tier B). Shared primary source for the Mitochondrial burden and ATP production entries; see Overlap map.
  9. Droese S, Hanley PJ, Brandt U. Ambivalent effects of diazoxide on mitochondrial ROS production at respiratory chain complexes I and III. — In vitro mechanistic study (Tier B). Key counter-evidence shared across the Mitochondrial burden, Oxidative stress, and ATP production entries; see Overlap map.
  10. Lucas AMB, de Lacerda Alexandre JV, Araujo MTS, et al. Diazoxide Modulates Cardiac Hypertrophy by Targeting H2O2 Generation and Mitochondrial Superoxide Dismutase Activity. — Animal study (Swiss mice, Tier B). Source for the Oxidative stress entry.
  11. Lemos Caldas FR, et al. Mitochondrial ATP-Sensitive Potassium Channel Opening Inhibits Isoproterenol-Induced Cardiac Hypertrophy. — Animal study (Swiss mice, Tier B). Source for the Oxidative stress entry.
  12. Guven C, et al. Diazoxide Attenuates Doxorubicin-Induced Cardiotoxicity in Cultured Rat Myocytes. — In vitro (rat myocytes, Tier B). Source for the Oxidative stress entry.
  13. Rajapakse N, et al. Diazoxide Pretreatment Induces Delayed Preconditioning in Astrocytes. — In vitro (astrocytes, Tier B). Source for the Oxidative stress entry.
  14. Du X, Xu H, Shi L, et al. Activation of ATP-sensitive potassium channels enhances DMT1-mediated iron uptake in SK-N-SH cells in vitro. — In vitro (SK-N-SH neuroblastoma cells, Tier B). Sole source for the Iron entry.
  15. PubMed search-listing page, query "diazoxide hemoglobin anemia." — Zero results. Used for the Oxygen delivery/utilization entry's null-search disclosure.
  16. PubMed search-listing page, query "diazoxide copper." — Zero results. Used for the Copper entry's evidence-gap disclosure.
  17. PubMed search-listing page, query "diazoxide AND (copper OR iron OR ferritin OR ceruloplasmin)." — 8 results, none addressing copper, ferritin, or ceruloplasmin; only the Du et al 2016 iron/DMT1 study was on-topic. Used for the Copper and Iron entries.
  18. PubMed search-listing page, query "diazoxide AND (microbiome OR microbiota OR gut flora)." — 3 results, none on-topic (setmelanotide trial mentioning diazoxide only as a comparator; unrelated colorectal-cancer and post-bariatric-hypoglycemia results). Used for the Gut microbiome risk entry's evidence-gap disclosure.
  19. PubMed search-listing page, query "diazoxide AND (carnitine OR thiamine OR vitamin)." — 83 results; none combine diazoxide with carnitine, thiamine, or a vitamin in an actual study of this drug. Used in the classical-nutrient mechanism screen (Step 2) to confirm no cofactor/vitamin depletion mechanism could be substantiated.
  20. Drugs.com. Diazoxide side effects page. — Consumer drug-information source (Tier D), reviewed for the circulating-claim audit only, never as support for a graded entry. No nutrient, vitamin, mineral, or "drug mugging" content found for diazoxide; confirms sodium/fluid retention and decreased hemoglobin/hematocrit as labeled effects.
  21. Europe PMC REST API, Semantic Scholar Graph API, Crossref API, and OpenAlex API, multiple queries across this review.Returned HTTP 403 (network egress policy denial or upstream failure, per this session's proxy status output) or HTTP 429 (target-side rate limiting) on every attempt throughout this review, across repeated wait-and-retry cycles, and could not be used as cross-check channels for any category; disclosed per entry above, most importantly for Copper and Gut microbiome risk.